Magazine Article | July 1, 2021

Against All Odds: Advancing From R&D To Phase 3

Source: Life Science Leader

By Sanjeev Luther

To pave a path in a field that is bound to be riddled with disappointments, uncertainties, and sometimes even utter failure, would deter most people from creating a career in biopharma. Harrowing statistics illustrate the hardships in successfully bringing a drug to market. In fact, over 90% of compounds never even enter Phase 1 clinical trials — a number that has not changed in decades. Advancing a pharmaceutical company is an uphill battle, with many challenges along the way from data analysis to FDA regulations to trial operations and beyond.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: